# Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis

> **NCT02542787** · PHASE2 · COMPLETED · sponsor: **Canbex Therapeutics Ltd** · enrollment: 160 (estimated)

## Conditions studied

- Spasticity in People With Multiple Sclerosis

## Interventions

- **DRUG:** VSN16R
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT02542787
- **Lead sponsor:** Canbex Therapeutics Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-08
- **Primary completion:** 2017-10
- **Final completion:** 2017-10
- **Target enrollment:** 160 (ESTIMATED)
- **Last updated:** 2018-03-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02542787

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02542787, "Study of VSN16R for the Treatment of Spasticity in Multiple Sclerosis". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT02542787. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*